

Amino Acids and Peptides. XXIII.¹⁾ Leu-Enkephalin Analogs Containing a Fluorinated Amino Acid at Position 2, 4 or 5

Mitsuko MAEDA,^a Koichi KAWASAKI,^{*,a} Takeo TAGUCHI,^b Yoshiro KOBAYASHI,^b Yoshihiro YAMAMOTO,^c Kazuhiro SHIMOKAWA,^c Masakatsu TAKAHASHI,^d Kaoru NAKAO,^d and Hiroshi KANETO^d

Faculty of Pharmaceutical Sciences, Kobe-Gakuin University,^a Ikawadani-cho, Nishi-ku, Kobe 651-21, Japan, Tokyo College of Pharmacy,^b Hachioji, Tokyo 192-03, Japan, Daikin Industries,^c Settsu, Osaka 566, Japan, and Faculty of Pharmaceutical Sciences, Nagasaki University,^d Bunkyo-machi, Nagasaki 852, Japan.

Received February 25, 1994; accepted April 12, 1994

Fluorinated analogs of Leu-enkephalin were synthesized by the solution method and the solid-phase method. The synthetic peptides were examined for opioid activities on mouse *vas deferens* and guinea pig ileum. Among the synthetic peptides, [D-Ala²,Leu(F₃)(2*R*,4*S*)⁵]enkephalin and [D-Ala²,Leu(F₃)(2*S*,4*R*)⁵]enkephalin exhibited potent opioid activity, and [Leu(F₃)(2*S*,4*R*)⁵]enkephalin exhibited high δ -receptor selectivity.

Keywords opioid peptide; fluorinated amino acid; enkephalin; opioid receptor; mouse *vas deferens*; guinea pig ileum

Fluorination of organic compounds has been used to modify pharmacological and biological activities. Previously we synthesized Leu-enkephalin(Leu-Enk, H-Tyr-Gly-Gly-Phe-Leu-OH) analogs containing fluorine in the aromatic ring of Tyr¹ or Phe⁴, and examined their opioid activity.²⁾ The *p*-fluorophenylalanine⁴ analog (H-Tyr-Gly-Gly-Phe(*p*-F)-Leu-OH) exerted more potent activity than Leu-Enk on mouse *vas deferens* (MVD) and on guinea pig ileum (GPI). Sasaki *et al.* reported that [D-Ala², Phe(*p*-F)⁴, D-Leu⁵]Enk had similar affinity to H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE) in opioid receptor binding assay.³⁾ Coy *et al.* found that [D-Ala², pentafluorophenylalanine⁴]Met-enkephalinamide exhibited more potent analgesic activity than the nonfluorinated parent compound.⁴⁾ Stimulated by these studies, we have synthesized several new Leu-Enk analogs with a fluorinated amino acid at position 2, 4 or 5.

H-Tyr-Val(F₆)-Gly-Phe-Leu-OH [I] and H-Tyr-D-Val(F₆)-Gly-Phe-Leu-OH [II], each containing the fluorinated aliphatic amino acid, 4,4,4,4,4-hexafluorovaline (Val(F₆)) at position 2, were synthesized by an automatic solid-phase method. H-Tyr-Gly-Gly-Phg(*o*-F)-Leu-OH [III] and H-Tyr-Gly-Gly-D-Phg(*o*-F)-Leu-OH [IV], each containing *o*-fluorophenylglycine (Phg(*o*-F)) at position 4, were also similarly synthesized. The starting materials were Boc-L-amino acids and alternatives, *i.e.* Boc-DL-Val(F₆)-OH and Boc-DL-Phg(*o*-F)-OH, which were derived from DL-Val(F₆) and DL-Phg(*o*-F), respectively. Solid phase peptide synthesis started with Boc-Leu-resin, to which Boc-amino acids or alternatives were sequentially coupled in the usual manner. Each protected peptide-resin was treated with HF,⁵⁾ and purified by HPLC. Crude H-Tyr-Gly-Gly-DL-Phg(*o*-F)-Leu-OH showed two main peaks (Fig. 1). The first and second peaks gave almost identical amino acid ratios after 6*N* HCl hydrolysis. But after aminopeptidase-M (AP-M) digestion, the amino acid ratio of the first peak was Tyr:Gly+Phg(*o*-F):Leu=1.00:2.72:0.95, while that of the second peak was Tyr:Gly+Phg(*o*-F):Leu=1.00:1.15:(not detected). This implies that the first peak was due to H-Tyr-Gly-Gly-Phg(*o*-F)-Leu-OH [III],

and the second peak to H-Tyr-Gly-Gly-D-Phg(*o*-F)-Leu-OH [IV]. H-Tyr-Val(F₆)-Gly-Phe-Leu-OH [I] and H-Tyr-D-Val(F₆)-Gly-Phe-Leu-OH [II] were each purified on a preparative HPLC column in the same way as described for III and IV.

H-Tyr-Gly-Gly-Phe-Leu(F₃)-OH, [Leu(F₃)⁵]Enk, contains 5,5,5-trifluoro-leucine(Leu(F₃)) instead of the C-terminal leucine. Since Leu(F₃) has two chiral carbons in the molecule, [Leu(F₃)⁵]Enk comprises four isomers (2*R*,4*R*), (2*R*,4*S*), (2*S*,4*S*) and (2*S*,4*R*), which correspond to H-Tyr-Gly-Gly-Phe-Leu(F₃)(2*R*,4*R*)-OH [V], H-Tyr-Gly-Gly-Phe-Leu(F₃)(2*R*,4*S*)-OH [VI], H-Tyr-Gly-Gly-Phe-Leu(F₃)(2*S*,4*S*)-OH [VII] and H-Tyr-Gly-Gly-Phe-Leu(F₃)(2*S*,4*R*)-OH [VIII], respectively. The 2*S*-isomer is a substitute for L-Leucine, and the 2*R*-isomer for D-Leucine. [D-Ala²,Leu(F₃)⁵]Enk also com-




Fig. 1. HPLC Profile of Crude H-Tyr-Gly-Gly-Phe(*o*-F)-Leu-OH
III: H-Tyr-Gly-Gly-Phg(*o*-F)-Leu-OH, IV: H-Tyr-Gly-Gly-D-Phg(*o*-F)-Leu-OH, Column: YMC-ODS (AM-303, 4.6 × 250 mm). Solvent A, 0.1% TFA/H₂O; B, 0.1% TFA/CH₃CN. A linear gradient: 25% B/A (0 min) → 45% B/A (30 min). Flow rate, 1.0 ml/min. UV, 220 nm.

prises four isomers: H-Tyr-D-Ala-Gly-Phe-Leu(F₃)-(2*R*,4*R*)-OH [IX], H-Tyr-D-Ala-Gly-Phe-Leu(F₃)-(2*R*,4*S*)-OH [X], H-Tyr-D-Ala-Gly-Phe-Leu(F₃)-(2*S*,4*S*)-OH [XI] and H-Tyr-D-Ala-Gly-Phe-Leu(F₃)-(2*S*,4*R*)-OH [XII]. These eight compounds (V, VI, VII, VIII, IX, X, XI, XII) were synthesized as shown in Fig. 2. Z-Tyr(Bzl)-Gly-Gly-Phe-N₂H₃ and Z-Tyr(Bzl)-D-Ala-Gly-Phe-N₂H₃, each prepared *via* stepwise elongation by the solution method, were each coupled with the corresponding Leu(F₃)(2*R*,4*R*; 2*R*,4*S*; 2*S*,4*S*; 2*S*,4*R*) by the usual azide method.⁷⁾ The crude protected peptides were hydrogenated over Pd catalyst and purified. We also synthesized [Leu(F₃)²]Leu-Enk analogs, H-Tyr-Leu(F₃)(2*R*,4*R*)-Gly-Phe-Leu-OH [XIII], H-Tyr-

Leu(F₃)(2*R*,4*S*)-Gly-Phe-Leu-OH [XIV], H-Tyr-Leu(F₃)(2*S*,4*S*)-Gly-Phe-Leu-OH [XV], H-Tyr-Leu(F₃)(2*S*,4*R*)-Gly-Phe-Leu-OH [XVI] by a manual solid-phase method using benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP)⁸⁾ as the coupling agent. Four isomers of Boc-Leu(F₃)-OH were used for the synthesis. The final deprotection was done by HF treatment and products were purified by HPLC. Each isomeric peptide had a distinct retention time on HPLC.

In a previous study, substitution with *o*-fluorotyrosine (Tyr(*o*-F)) or *m*-fluorotyrosine (Tyr(*m*-F)) for Tyr at position 1, and substitution with *p*-fluorophenylalanine (Phe(*p*-F)) for Phe at position 4, tended to increase opioid




Fig. 2. Synthetic Scheme for V–XII

MA: mixed anhydride method.

TABLE I. Inhibitory Effects of the Synthetic Peptides on the Electrically Induced Contractions of Isolated Smooth Muscle Preparations

| Compound | GPI | | MVD | | GPI (IC ₅₀) MVD (IC ₅₀) |
|--|-----------------------|-------------------|-----------------------|-------------------|--|
| | IC ₅₀ (nM) | Relative activity | IC ₅₀ (nM) | Relative activity | |
| Leu-Enk | 209 | 100 | 10 | 100 | 21 |
| [D-Leu ⁵]Enk | 1000 | 21 | 21 | 48 | 48 |
| DALDA | 155 | 135 | 830 | 1 | 0.2 |
| DTLET | 20 | 1045 | 0.07 | 14300 | 286 |
| I [Val(F ₆) ²]Leu-Enk | Inactive | — | 26800 | 0.04 | — |
| II [D-Val(F ₆) ²]Leu-Enk | 1300 | 16 | 775 | 1 | 2 |
| III [Phg(<i>o</i> -F) ⁴]Leu-Enk | Inactive | — | > 100 μM | < 0.01 | — |
| IV [D-Phg(<i>o</i> -F) ⁴]Leu-Enk | > 100 μM | < 0.2 | 8400 | 0.1 | — |
| V [Leu(F ₃)(2 <i>R</i> ,4 <i>R</i>) ⁵]Enk | 2650 | 8 | 113 | 9 | 23 |
| VI [Leu(F ₃)(2 <i>R</i> ,4 <i>S</i>) ⁵]Enk | 4310 | 5 | 74 | 14 | 58 |
| VII [Leu(F ₃)(2 <i>S</i> ,4 <i>S</i>) ⁵]Enk | 398 | 53 | 25 | 40 | 16 |
| VIII [Leu(F ₃)(2 <i>S</i> ,4 <i>R</i>) ⁵]Enk | 1010 | 21 | 7 | 143 | 144 |
| IX [D-Ala ² ,Leu(F ₃)(2 <i>R</i> ,4 <i>R</i>) ⁵]Enk | 43 | 486 | 9 | 127 | 5 |
| X [D-Ala ² ,Leu(F ₃)(2 <i>R</i> ,4 <i>S</i>) ⁵]Enk | 35 | 597 | 2 | 500 | 18 |
| XI [D-Ala ² ,Leu(F ₃)(2 <i>S</i> ,4 <i>S</i>) ⁵]Enk | 43 | 486 | 5 | 200 | 9 |
| XII [D-Ala ² ,Leu(F ₃)(2 <i>S</i> ,4 <i>R</i>) ⁵]Enk | 33 | 633 | 2 | 500 | 17 |
| XIII [Leu(F ₃)(2 <i>R</i> ,4 <i>R</i>) ²]Leu-Enk | 75 | 279 | 117 | 9 | 0.6 |
| XIV [Leu(F ₃)(2 <i>R</i> ,4 <i>R</i>) ²]Leu-Enk | 303 | 69 | 558 | 2 | 0.5 |
| XV [Leu(F ₃)(2 <i>S</i> ,4 <i>S</i>) ²]Leu-Enk | 22557 | 1 | 12708 | 0.1 | 2 |
| XVI [Leu(F ₃)(2 <i>S</i> ,4 <i>R</i>) ²]Leu-Enk | 3467 | 6 | 5041 | 0.2 | 0.7 |
| XVII [Tyr(<i>o</i> -F) ¹ ,Phe(<i>p</i> -F) ⁴]Leu-Enk | 360 | 58 | 19 | 53 | 19 |
| XVIII [Tyr(<i>m</i> -F) ¹ ,Phe(<i>p</i> -F) ⁴]Leu-Enk | 3000 | 7 | 398 | 3 | 8 |
| XIX [Phe(<i>p</i> -F) ³]DALDA | 2100 | 10 | 106 | 9 | 20 |
| XX [Phe(<i>p</i> -F) ⁴]DTLET | 24 | 871 | 0.4 | 2500 | 60 |

activity. This encouraged us to synthesize the analogs, H-Tyr(*o*-F)-Gly-Gly-Phe(*p*-F)-Leu-OH [XVII], H-Tyr(*m*-F)-Gly-Gly-Phe(*p*-F)-Leu-OH [XVIII], H-Tyr-D-Arg-Phe(*p*-F)-Lys-NH₂ [XIX], whose parent peptide H-Tyr-D-Arg-Phe-Lys-NH₂(DALDA)⁹⁾ has high μ -selectivity, and H-Tyr-D-Thr-Gly-Phe(*p*-F)-Leu-Thr-OH [XX], whose parent peptide H-Tyr-D-Thr-Gly-Phe-Leu-Thr-OH (DTLET)¹⁰⁾ has high δ -selectivity. These syntheses were also carried out by the solid-phase method as mentioned above.

The IC₅₀ values, the relative activity and the IC₅₀(GPI)/IC₅₀(MVD) ratio are summarized in Table I. All compounds, except I and III in the GPI test, dose-dependently inhibited electrically induced contraction of both GPI and MVD preparations.

In line with the earlier reports on DALDA, and DTLET, we found that DALDA possesses typical μ -opioid receptor agonistic activity and DTLET a typical δ -receptor agonist characteristic; the value of IC₅₀(GPI)/IC₅₀(MVD) ratio of DALDA and DTLET were 0.2 and 286, respectively. The inhibitory effects of compounds I—IV were lower than that of Leu-Enk in GPI and MVD preparations. The IC₅₀ values of GPI and MVD indicate that the [Leu(F₃)⁵]Enk compounds V—VIII, as compared with the parent compound Leu-Enk, showed decreased potencies in inhibiting the contractions of the tissue preparations with the exception of a slight increase in the potency of VIII in MVD preparations. Consequently, the δ -receptor selectivity of compound VIII was 7 times that of Leu-Enk.¹¹⁾ Meanwhile, [D-Ala²,Leu-(F₃)⁵]Enk analogs IX—XII, obtained by introducing D-Ala² into [Leu(F₃)⁵]Enk analogs V—VIII possessing weak activity, produced higher inhibitory activity than Leu-Enk in both preparations, and more stable potentiation of the activity was found in the GPI preparation than in the MVD. Thus, the potentiation by the D-Ala² substitution may be attributed to the increase of resistance to enzymatic hydrolysis of the Tyr¹-Gly² bond. Fluorination of a drug molecule may modify the hydrophobic character and the electron density of the drug molecule¹²⁾ and may increase the activity of the drug. Coy *et al.*⁴⁾ and Walker *et al.*¹³⁾ reported enhancement of the pharmacological effect by the fluorination of [D-Ala²]Met-enkephalinamide and dynorphin 1—13, respectively. The substitution of fluorinated Leu for Gly², as in compounds XIII—XVI, led to a substantial decrease in ability to inhibit the contraction of both preparations, except that compound XIII showed a somewhat increased activity in GPI preparation. The selectivity of a series of [Leu-(F₃)²]Enk analogs XIII—XVI, for μ -receptor was at least 10 times that of [Leu(F₃)⁵]Enk and Leu-Enk. Fluorination at Tyr¹ and Phe⁴ of Leu-Enk, analogs XVII and XVIII, and that at Phe³ of DALDA, compound XIX, resulted in decreased inhibitory activity in both preparations. Similarly, monofluorinated DTLET at Phe⁴, compound XX, showed a weaker inhibitory effect on the contractions of MVD preparation than the parent nonfluorinated DTLET.

The results, taken together, suggest that the structural changes of the peptide including the alteration of molecular size, conformation, electron density and hydro-

phobic character of the peptide, due to the introduction of fluorine tends to decrease the affinity for opioid receptors, and in some cases, changes the selectivity for the receptor types *in vitro*; however, from the differences among Leu-Enk and [Leu(F₃)⁵]Enk analogs V—VIII in inhibiting the contractions of the preparations, the configuration of [Leu(F₃)(2*S*,4*R*)⁵]Enk seems to be more capable of binding to δ -opioid receptors of MVD than that of Leu-Enk or other [Leu(F₃)⁵]Enk. Additionally, the slight differences in the binding to GPI preparation among V—VIII as well as IX—XII indicate that the μ -opioid receptors in GPI preparation seem to be more flexible than the δ -receptors in MVD in accommodating the structural changes caused by fluorination of the ligands.

Experimental

Melting points are uncorrected. Solvent systems for ascending TLC on Silica gel G (type 60, E. Merck) are indicated as follows: $R_f^1 = n$ -BuOH-AcOH-H₂O (4:1:5, upper phase), $R_f^3 = \text{CHCl}_3$ -MeOH-H₂O (8:3:1, lower phase), $R_f^5 = \text{CHCl}_3$ -AcOH-MeOH (90:2:8). Optical rotations were measured with a JASCO DIP-360 polarimeter. RP-HPLC was conducted with a Waters 600 on YMC Pack AQ-ODS-5 using a mixture of 0.1% TFA-containing CH₃CN/H₂O as an eluent. Synthetic peptides were hydrolyzed in 6*N* HCl at 110 °C for 24 h. The amino acid compositions of acid and enzymatic hydrolysates were determined with a Hitachi 835 amino acid analyzer. Positive ion mass spectra were measured with a Hitachi model M-1000 quadrupole mass spectrometer. Negative ion mass spectra were measured with a Hitachi model M-2000 double-focusing mass spectrometer. 4,4,4,4,4-Hexafluoro-DL-valine and *o*-fluoro-DL-phenylglycine were purchased from PCR Incorporated. AP-M was purchased from Boehringer Mannheim GmbH. AP-M digestion was done by the method reported in our previous paper.¹⁴⁾

Solid-Phase Peptide Synthesis Peptides were prepared by use of the Boc strategy. Resins were purchased from Peptide Institute, Inc. *p*-Methylbenzhydrylamine-resin (NH₂ content, 0.63 meq/g) was used for preparation of XIX. Chloromethylated polystyrene (divinylbenzene 1%, Cl content, 0.77 meq/g) was used for preparation of C-terminal carboxyl-free peptides. Boc-amino acid was introduced on chloromethylated resin by the cesium salt method.¹⁵⁾ For side chain protection, the Bzl group was used for Tyr and Thr, and the tosyl or nitro group was used for Arg. Final deprotection was performed by HF treatment. Synthetic peptide-resin was treated with 10% anisole/HF at 0 °C for 90 min. After removal of HF, the residue was extracted with 5% AcOH and the mixture was filtered. The filtrate was washed with ether and lyophilized. Crude peptides were purified by RP-HPLC. Peptides I, II, III, IV, XVII and XVIII were prepared by the automatic peptide synthesizer. Other peptides were prepared by the manual method using the protocol shown below. Peptides XVIII, XIV, XV and XVI were prepared using BOP⁷⁾ as a coupling agent. Final deprotection was performed by the HF method as described.

| step | reagents | reaction time (min) | |
|------|--|---------------------|-----|
| 1 | 5% NMM/DCM | 10 | × 2 |
| 2 | DCM | 3 | × 3 |
| 3 | Boc-amino acid (2 eq) in DMF (or DCM) 1 M DCC/DCM, 1 M HOBt/DMF [or 1 M BOP/DMF (2 eq) and 1.5% DIEA (4 eq)] | 120 | |
| 4 | DMF | 3 | × 2 |
| 5 | 50% MeOH/DCM | 5 | × 3 |
| 6 | DCM | 2 | 1 |
| 7 | 50% TFA/DCM | 2 | 1 |
| | | 45 | 1 |
| 8 | DCM | 3 | × 3 |

Boc-DL-Val(F₆)-OH Prepared from 4,4,4,4,4-hexafluoro-DL-valine (0.8 g, 3.6 mmol) and 2-*tert*-butoxycarbonyloxymino-2-phenylacetone-trile¹⁶⁾ (Boc-ON, 1.1 g, 4.3 mmol) in the usual manner. Precipitated from AcOEt/petroleum ether. Yield 1.07 g (93.1%), mp 116 °C, R_f^5 0.92. MS m/z : 324 (M-H)⁻.

Boc-DL-Phe(*o*-F)-OH Prepared from H-DL-Phe(*o*-F)-OH (0.5 g,

3 mmol) and Boc-ON (0.9 g, 3.6 mmol) in the usual manner.¹⁶⁾ Precipitated from AcOEt/petroleum ether. Yield 0.8 g (99%), mp 121–124 °C, R_f^3 0.66. MS m/z : 268 (M–H)[–].

H-Tyr-Val(F₆)-Gly-Phe-Leu-OH [I] Prepared by the synthesizer and obtained in a pure form from the crude mixture of I and II by preparative HPLC. Yield 55 mg (7.4%), R_f^1 0.75, $[\alpha]_D^{27} + 15.4^\circ$ ($c=1.0$, H₂O). MS m/z : 705 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.67, Val(F₆) 0.68, Gly 1.00, Phe 1.00, Leu 1.08 (average recovery 80%). Amino acid ratios in AP-M digest: Tyr 1.00, Val(F₆) 0.22, Gly 0.24, Phe 0.26, Leu 0.32 (recovery of Tyr 70%).

H-Tyr-D-Val(F₆)-Gly-Phe-Leu-OH [II] Prepared as described above. Yield 58 mg (15.6%), R_f^1 0.78, $[\alpha]_D^{27} + 22.9^\circ$ ($c=1.0$, H₂O). MS m/z : 705 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.63, Val(F₆) 0.84, Gly 0.95, Phe 1.00, Leu 0.98 (average recovery 68%). No amino acid was detected in an AP-M digest.

H-Tyr-Gly-Gly-Phg(o-F)-Leu-OH [III] Prepared by the synthesizer and obtained from a mixture of crude III and IV by HPLC. Yield 45 mg (7.6%), R_f^1 0.76, $[\alpha]_D^{27} + 8.4^\circ$ ($c=1.0$, H₂O). MS m/z : 559 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.98, Gly + Phg(o-F) 3.38, Leu 1.08 (average recovery 83%). Amino acid ratios in an AP-M digest: Tyr 1.00, Gly + Phg(o-F) 2.72, Leu 0.95 (recovery of Tyr 77%).

H-Tyr-Gly-Gly-D-Phg(o-F)-Leu-OH [IV] Prepared as described above. Yield 51 mg (8.6%), R_f^1 0.76, $[\alpha]_D^{27} + 16.8^\circ$ ($c=1.0$, H₂O). MS m/z : 559 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.74, Gly + Phg(o-F) 3.21, Leu 1.00 (average recovery 81.4%). Amino acid ratios in AP-M digest: Tyr 1.00, Gly + Phg(o-F) 1.15, Leu not detected (recovery of Tyr 92%).

Z-Gly-Phe-OMe Z-Gly-OH (2.1 g, 10 mmol) and H-Phe-OMe·HCl (2.2 g, 10 mmol) were coupled in *N,N*-dimethyl formamide (DMF) by the mixed anhydride method in the usual manner.¹⁷⁾ Yield 3.63 g (98%), sirupy material, R_f^3 0.90, $[\alpha]_D^{27} - 19.4^\circ$ ($c=1.0$, MeOH). MS m/z : 371 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Gly 1.02, Phe 1.00 (average recovery 87%).

Z-Gly-Gly-Phe-OMe Prepared from Z-Gly-OH (480 mg, 2.2 mmol) and H-Gly-Phe-OMe·HCl (600 mg, 2.2 mmol) by the mixed anhydride method. Yield 654 mg (70%), sirupy material, R_f^3 0.79, $[\alpha]_D^{27} - 45.6^\circ$ ($c=1.0$, MeOH). MS m/z : 428 (M+H)[–]. Amino acid ratios in an acid hydrolysate: Gly 2.02, Phe 1.00 (average recovery 84%).

Z-D-Ala-Gly-Phe-OMe Prepared from Z-D-Ala-OH (760 mg, 3.4 mmol) and H-Gly-Phe-OMe·HCl (930 mg, 3.4 mmol) by the mixed anhydride method. Precipitated from AcOEt/petroleum ether. Yield 1.18 g (78%), mp 102 °C, R_f^3 0.64, $[\alpha]_D^{27} - 56.9^\circ$ ($c=1.0$, MeOH). MS m/z : 442 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Ala 1.00, Gly 1.04, Phe 1.00 (average recovery 93%).

Z-Tyr(Bzl)-Gly-Gly-Phe-OMe Prepared from Z-Tyr(Bzl)-OH (1.05 g, 2.6 mmol) and H-Gly-Gly-Phe-OMe (prepared from 1.11 g of Z-Gly-Gly-Phe-OMe by hydrogenation) by the mixed anhydride method. Precipitated from AcOEt/petroleum ether. Yield 1.28 g (72%), mp 140–142 °C, R_f^3 0.64, $[\alpha]_D^{27} - 23.1^\circ$ ($c=1.0$, MeOH). MS m/z : 681 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.84, Gly 2.06, Phe 1.00 (average recovery 81%).

Z-Tyr(Bzl)-D-Ala-Gly-Phe-OMe Prepared from Z-Tyr(Bzl)-OH (1.05 mg, 2.6 mmol) and H-D-Ala-Gly-Phe-OMe (prepared from 840 mg of Z-D-Ala-Gly-Phe-OMe by hydrogenation) by the mixed anhydride method. Yield 0.98 g (54%), mp 140–145 °C, R_f^3 0.72, $[\alpha]_D^{27} - 46.0^\circ$ ($c=1.0$, MeOH). MS m/z : 695 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.82, Ala 0.99, Gly 1.10, Phe 1.00 (average recovery 85%).

Z-Tyr(Bzl)-Gly-Gly-Phe-N₂H₃ Prepared from Z-Tyr(Bzl)-Gly-Phe-OMe (680 mg, 1 mmol) and NH₂NH₂·H₂O (0.15 ml, 3 mmol) in MeOH (15 ml) in the usual manner. Yield 470 mg (69%), mp 194 °C, R_f^3 0.59, $[\alpha]_D^{27} - 23.9^\circ$ ($c=1.0$, MeOH). MS m/z : 681 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.78, Gly 2.06, Phe 1.00 (average recovery 80%).

Z-Tyr(Bzl)-D-Ala-Gly-Phe-N₂H₃ Prepared from Z-Tyr(Bzl)-D-Ala-Gly-Phe-OMe (695 mg, 1 mmol) and NH₂NH₂·H₂O (0.15 ml, 3 mmole) in MeOH (15 ml) in the usual manner. Yield 540 mg (78%), mp 204 °C, R_f^3 0.46, $[\alpha]_D^{27} - 50.4^\circ$ ($c=1.0$, MeOH). MS m/z : 695 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.77, Ala 0.98, Gly 1.00, Phe 1.00 (average recovery 75%).

H-Tyr-Gly-Gly-Phe-Leu(F₃)(2R,4R)-OH [V] Isoamyl nitrite (60 μl, 0.6 mmol) was added to a DMF solution (5 ml) of Z-Tyr(Bzl)-Gly-Gly-Phe-N₂H₃ (410 mg, 0.6 mmol) and 6N HCl/dioxane (0.5 ml) at

–10 °C and the mixture was stirred for 10 min. H-Leu(F₃)(2R,4R)-OH (92.5 mg, 0.5 mmol) dissolved in a mixture of Et₃N (91 μl, 0.66 mmol), H₂O (5 ml) was added to the mixture and the whole was stirred for 20 h in a cold room. The solvent was removed *in vacuo* and the residue was washed with H₂O. The protected peptide was then hydrogenated on Pd catalyst in MeOH to give H-Tyr-Gly-Gly-Phe-Leu(F₃)(2R,4R)-OH, followed by HPLC. Yield 232 mg (59%), R_f^1 0.35, $[\alpha]_D^{27} + 46.1^\circ$ ($c=1.0$, H₂O). MS m/z : 610 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.79, Gly 2.00, Phe 1.00, Leu(F₃) 0.82 (average recovery 75%).

The following compounds were prepared in the same way.

H-Tyr-Gly-Gly-Phe-Leu(F₃)(2R,4S)-OH [VI] Yield 187 mg (52%), R_f^1 0.35, $[\alpha]_D^{27} + 31.0^\circ$ ($c=1.0$, H₂O). MS m/z : 610 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.80, Gly 1.99, Phe 1.00, Leu(F₃) 0.80 (average recovery 68%).

H-Tyr-Gly-Gly-Phe-Leu(F₃)(2S,4S)-OH [VII] Yield 192 mg (59%), R_f^1 0.35, $[\alpha]_D^{27} + 8.8^\circ$ ($c=1.0$, H₂O). MS m/z : 610 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.78, Gly 1.99, Phe 1.00, Leu(F₃) 0.81 (average recovery 70%).

H-Tyr-Gly-Gly-Phe-Leu(F₃)-OH [VIII] Yield 181 mg (50%), R_f^1 0.35, $[\alpha]_D^{27} + 15.9^\circ$ ($c=1.0$, H₂O). MS m/z : 610 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.72, Gly 2.02, Phe 1.00, Leu(F₃) 0.79 (average recovery 75%).

H-Tyr-D-Ala-Gly-Phe-Leu(F₃)(2R,4R)-OH [IX] Prepared from Z-Tyr(Bzl)-D-Ala-Gly-Phe-N₂H₃ (410 mg, 0.6 mmol) and the corresponding H-Leu(F₃)-OH (92.5 mg, 0.5 mmol) in the same way as described for V. Yield 99 mg (64%), R_f^1 0.31, $[\alpha]_D^{27} + 69.1^\circ$ ($c=1.0$, H₂O). MS m/z : 624 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.97, Ala 0.94, Gly 1.12, Phe 1.00, Leu(F₃) 1.03 (average recovery 96%).

The following compounds were prepared in the same way.

H-Tyr-D-Ala-Gly-Phe-Leu(F₃)(2R,4S)-OH [X] Yield 88 mg (56%), R_f^1 0.34, $[\alpha]_D^{27} + 58.4^\circ$ ($c=1.0$, H₂O). MS m/z : 624 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.89, Ala 0.96, Gly 1.10, Phe 1.00, Leu(F₃) 1.00 (average recovery 96%).

H-Tyr-D-Ala-Gly-Phe-Leu(F₃)(2S,4S)-OH [XI] Yield 97 mg (62%), R_f^1 0.34, $[\alpha]_D^{27} + 32.9^\circ$ ($c=1.0$, H₂O). MS m/z : 624 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.86, Ala 0.99, Gly 0.95, Phe 1.00, Leu(F₃) 1.04 (average recovery 86%).

H-Tyr-D-Ala-Gly-Phe-Leu(F₃)(2S,4R)-OH [XII] Yield 114 mg (73%), R_f^1 0.34, $[\alpha]_D^{27} + 40.2^\circ$ ($c=1.0$, H₂O). MS m/z : 624 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.87, Ala 0.97, Gly 0.99, Phe 1.00, Leu(F₃) 1.05 (average recovery 90%).

Boc-Leu(F₃)(2R,4R)-OH Prepared from H-Leu(F₃)(2R,4R)-OH (52 mg, 0.28 mmol) and (Boc)₂O (180 mg, 0.84 mmol) in the usual manner.¹⁸⁾ Precipitated from AcOEt/petroleum ether. Yield 80 mg (100%), amorphous material, R_f^3 0.69, $[\alpha]_D^{24} + 31.4^\circ$ ($c=1.0$, MeOH). MS m/z : 284 (M–H)[–].

Boc-Leu(F₃)(2R,4S)-OH Prepared from H-Leu(F₃)(2R,4S)-OH (101 mg, 0.55 mmol) and (Boc)₂O (360 mg, 1.65 mmol) in the usual manner. Precipitated from AcOEt/petroleum ether. Yield 157 mg (100%), amorphous material, R_f^3 0.80, $[\alpha]_D^{24} + 1.2^\circ$ ($c=1.0$, MeOH). MS m/z : 284 (M–H)[–].

Boc-Leu(F₃)(2S,4S)-OH Prepared from H-Leu(F₃)(2S,4S)-OH (39 mg, 0.21 mmol) and (Boc)₂O (138 mg, 0.63 mmol) in the usual manner. Precipitated from AcOEt/petroleum ether. Yield 61 mg (100%), amorphous material, R_f^3 0.76, $[\alpha]_D^{24} - 35.6^\circ$ ($c=1.0$, MeOH). MS m/z : 284 (M–H)[–].

Boc-Leu(F₃)(2S,4R)-OH Prepared from H-Leu(F₃)(2S,4R)-OH (48 mg, 0.26 mmol) and (Boc)₂O (170 mg, 0.77 mmol) in the usual manner. Precipitated from AcOEt/petroleum ether. Yield 74 mg (100%), amorphous material, R_f^3 0.69, $[\alpha]_D^{24} - 8.4^\circ$ ($c=1.0$, MeOH). MS m/z : 284 (M–H)[–].

H-Tyr-Leu(F₃)(2R,4R)-Gly-Phe-Leu-OH [XIII] Prepared by the manual solid-phase method using BOP as the coupling agent. Yield 38 mg (21%), R_f^1 0.46, $[\alpha]_D^{27} + 13.8^\circ$ ($c=1.0$, H₂O). MS m/z : 666 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.73, Leu(F₃) 1.09, Gly 1.08, Phe 1.00, Leu 1.01 (average recovery 95.0%).

The following compounds were prepared in the same way.

H-Tyr-Leu(F₃)(2R,4S)-Gly-Phe-Leu-OH [XIV] Yield 53 mg (29%), R_f^1 0.46, $[\alpha]_D^{27} + 38.5^\circ$ ($c=1.0$, H₂O). MS m/z : 666 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.73, Leu(F₃) 0.89, Gly 1.08, Phe 1.00, Leu 1.00 (average recovery 78%).

H-Tyr-Leu(F₃)(2S,4S)-Gly-Phe-Leu-OH [XV] Yield 25 mg (48%), R_f^1 0.46, $[\alpha]_D^{27} - 53.2^\circ$ ($c=1.0$, H₂O). MS m/z : 666 (M+H)⁺. Amino

acid ratios in an acid hydrolysate: Tyr 0.73, Leu(F₃) 1.03, Gly 0.92, Phe 1.00, Leu 1.01 (average recovery 68%).

H-Tyr-Leu(F₃)(2S,4R)-Gly-Phe-Leu-OH [XVI] Yield 34 mg (60%), *R*_f¹ 0.46, [α]_D²⁷ -6.0° (*c*=1.0, H₂O). MS *m/z*: 666 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.72, Leu(F₃) 1.03, Gly 0.92, Phe 1.00, Leu 1.05 (average recovery 80%).

H-Tyr(o-F)-Gly-Phe(p-F)-Leu-OH [XVII] Prepared by the synthesizer. Yield 72 mg (12%), *R*_f¹ 0.52, [α]_D²⁷ +18.2° (*c*=1.0, H₂O). MS *m/z*: 591 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr(o-F) 0.72, Gly 1.86, Phe(p-F) 0.73, Leu 1.00 (average recovery 77%).

The following compounds were prepared in the same way.

H-Tyr(m-F)-Gly-Phe(p-F)-Leu-OH [XVIII] Yield 150 mg (24%), *R*_f¹ 0.58, [α]_D²⁷ +16.3° (*c*=1.0, H₂O). MS *m/z*: 591 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr(m-F) 0.94, Gly 1.88, Phe(p-F) 1.04, Leu 1.00 (average recovery 70%).

H-Tyr-D-Arg-Phe(p-F)-Lys-NH₂ [XIX] For side chain protection, a nitro group was used for Arg and a 2-chlorobenzoyloxycarbonyl group was used for Lys. Yield 242 mg (32%), *R*_f¹ 0.64, [α]_D²⁷ +3.8° (*c*=1.0, H₂O). MS *m/z* 765 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.97, Lys 1.01, Phe(p-F) 0.96, Arg 1.00 (average recovery 89%).

H-Tyr-D-Thr-Gly-Phe(p-F)-Leu-Thr-OH [XX] Yield 420 mg (58%), *R*_f¹ 0.34, [α]_D²⁷ +20.5° (*c*=1.0, H₂O). MS *m/z*: 720 (M+H)⁺. Amino acid ratios in an acid hydrolysate: Tyr 0.87, Thr 1.67, Gly + Phe(p-F) 1.97, Leu 1.03 (average recovery 91%).

Bioassay Male guinea pigs weighing 300 to 350 g (Otsubo Exp. Animal) were killed by a blow to the head and segments (about 4 cm) of the ileum 10 to 15 cm from the ileo-cecal valve were isolated. The longitudinal muscle with myenteric plexus of GPI was prepared as described by Rang.¹⁹ MVD was isolated from male ddY mice weighing 30–35 g (Otsubo Exp. Animal). Both preparations were mounted in a 10 ml organ bath filled with Krebs–Henseleit solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl₂, 1.1 mM KH₂PO₄, 2.4 mM MgSO₄, 25 mM NaHCO₃, 11 mM glucose) for GPI or Mg²⁺-free Krebs–Henseleit solution for MVD, and kept at 37°C. Inhibitory effects of the test compounds on the electrically induced contractions of both preparations were estimated from concentration–response curves and expressed as IC₅₀. Details of the procedures were reported in our previous paper.^{2b)}

This work was supported in part by a grant from The Science Research Promotion Fund of the Japan Private School Promotion Foundation.

References and Notes

- Standard abbreviations for amino acids, protecting groups, and peptides are used [*Eur. J. Biochem.*, **138**, 9 (1984)]. Other abbreviations include: DMF = *N,N*-dimethylformamide, Bzl = benzyl, DCM = dichloromethane.
- a) M. Maeda, K. Kawasaki, J. Watanabe, H. Kaneto, *Chem. Pharm. Bull.*, **37**, 826 (1989); b) J. Watanabe, H. Kaneto, M. Maeda, T. Tsuji, K. Kawasaki, *J. Pharmacobio-Dyn.*, **8**, 975 (1985).
- H. Sasaki, H. Kohno, Y. Ohkubo, K. Suzuki, *Chem. Pharm. Bull.*, **38**, 3162 (1990).
- D. H. Coy, A. J. Kastin, M. J. Walker, R. McGivern, C. A. Sandman, *Biochem. Biophys. Res. Commun.*, **83**, 977 (1978).
- S. Sakakibara, Y. Shimonishi, Y. Kishida, M. Okada, H. Sugihara, *Bull. Chem. Soc. Jpn.*, **40**, 2164 (1967).
- T. Taguchi, A. Kawara, S. Watanabe, Y. Oki, H. Fukushima, Y. Kobayashi, M. Okada, K. Ohta, Y. Iitaka, *Tetrahedron Lett.*, **27**, 5117 (1986).
- J. Honzl, J. Rudinger, *Collect. Czech. Chem. Commun.*, **26**, 2333 (1961).
- a) B. Castro, J. R. Dormoy, G. Evin, C. Selve, *Tetrahedron Lett.*, **1976**, 1219; b) A. Fournierf, C. Wang, A. M. Felix, *Int. J. Peptide Protein Res.*, **31**, 86 (1988).
- P. W. Schiller, T. M.-D. Nguyen, N. N. Chung, C. Lemieux, *J. Med. Chem.*, **32**, 698 (1989).
- J.-M. Zajac, G. Gacel, F. Petit, P. Dodey, P. Rossignol, B. P. Roques, *Biochem. Biophys. Res. Commun.*, **111**, 390 (1983).
- J. Watanabe, S. Tokuyama, M. Takahashi, H. Kaneto, M. Maeda, K. Kawasaki, T. Taguchi, Y. Kobayashi, Y. Yamamoto, K. Shimokawa, *J. Pharmacobio-Dyn.*, **14**, 101 (1991).
- a) K. Akahane, T. Kamijo, K. Iizuka, T. Taguchi, Y. Kobayashi, Y. Kiso, H. Umeyama, *Chem. Pharm. Bull.*, **36**, 3447 (1988); b) E. W. Petrillo, Jr., M. A. Ondetti, *Med. Res. Rev.*, **2**, 1 (1982); c) S. Thaisrivongs, D. T. Pals, W. M. Kati, S. R. Turner, L. M. Thomasco, W. Watt, *J. Med. Chem.*, **29**, 2080 (1986); d) N. Peet, J. P. Burkhart, M. R. Angelastro, E. L. Giroux, S. Mehdi, P. Bey, M. Kolb, B. Neises, D. Schirlin, *ibid.*, **33**, 394 (1990); e) T. Ueda, C. M. Kam, J. C. Powers, *Biochem. J.*, **265**, 539 (1990); f) C. P. Govardhan, R. H. Abeles, *Arch. Biochem. Biophys.*, **280**, 137 (1990).
- J. M. Walker, D. H. Coy, E. A. Young, G. Baldrighi, S. F. Siegel, W. D. Bowen, H. Akil, *Peptides*, **8**, 811 (1987).
- K. Kawasaki, M. Maeda, J. Watanabe, H. Kaneto, *Chem. Pharm. Bull.*, **36**, 1766 (1988).
- B. F. Gisin, *Helv. Chim. Acta*, **56**, 1476 (1973).
- M. Itoh, D. Hasegawa, T. Kamiya, *Bull. Chem. Soc. Jpn.*, **50**, 718 (1977).
- J. R. Vaughan, Jr., R. L. Osato, *J. Am. Chem. Soc.*, **74**, 676 (1952).
- D. S. Tarbell, T. Yamamoto, B. M. Pope, *Proc. Natl. Acad. Sci. U.S.A.*, **69**, 730 (1972).
- H. P. Rang, *Br. J. Pharmacol.*, **22**, 356 (1964).